CAS 56124-62-0
:Valrubicin
Description:
Valrubicin, with the CAS number 56124-62-0, is an anthracycline derivative primarily used in the treatment of bladder cancer. It is characterized by its ability to intercalate into DNA, thereby inhibiting DNA and RNA synthesis, which ultimately leads to cell death. Valrubicin is administered intravesically, meaning it is delivered directly into the bladder, allowing for localized treatment with reduced systemic toxicity compared to other chemotherapeutic agents. The compound exhibits a unique mechanism of action that involves the generation of free radicals, contributing to its cytotoxic effects. Valrubicin is known for its potential side effects, which may include local irritation, bladder spasms, and systemic effects such as nausea and vomiting. Its efficacy is often evaluated in patients with superficial bladder tumors, and it is considered when other treatment options are not suitable. Overall, Valrubicin represents a targeted approach in cancer therapy, particularly for urothelial carcinoma, highlighting the importance of localized treatment strategies in oncology.
Formula:C34H36F3NO13
InChI:InChI=1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,14,17,19,22,27,41,43,45,47H,4-5,9-13H2,1-3H3,(H,38,46)/t14-,17-,19-,22-,27+,33-/m0/s1
InChI key:InChIKey=ZOCKGBMQLCSHFP-KQRAQHLDSA-N
SMILES:O([C@@H]1C2=C(C(O)=C3C(=C2O)C(=O)C=4C(C3=O)=CC=CC4OC)C[C@](C(COC(CCCC)=O)=O)(O)C1)[C@H]5C[C@H](NC(C(F)(F)F)=O)[C@H](O)[C@H](C)O5
Synonyms:- AD 32
- Pentanoic acid, 2-[(2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-α-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethyl ester
- Pentanoic acid, 2-[(2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(2,2,2-trifluoroacetyl)amino]-α-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethyl ester
- Pentanoic acid, 2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-α-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethyl ester, (2S-cis)-
- Antibiotic AD 32
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 9 products.
Valrubicin
CAS:Antibiotics nesoiFormula:C34H36F3NO13Color and Shape:Orange Red Crystalline PowderMolecular weight:723.21387Valrubicin
CAS:2-oxo-2-((2S,4S)-2,5,12-trihydroxy-4-(((2R,4S,5S,6S)-5-hydroxy-6-methyl-4-(2,2,2-trifluoroacetamido)tetrahydro-2H-pyran-2-yl)oxy)-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)ethyl pentanoateFormula:C34H36F3NO13Purity:98%Molecular weight:723.64Valrubicin
CAS:Formula:C34H36F3NO13Purity:95.0 - 103.0 % (dried basis)Color and Shape:Orange to orange-red crystalline powderMolecular weight:723.64Valrubicin
CAS:Valrubicin (AD-32) (AD 32) inhibits TPA- and PDBu-induced PKC activation (IC50s: 0.85 and 1.25 μM) and has antitumor and anti-inflammatory activity.Formula:C34H36F3NO13Purity:98.63%Color and Shape:SolidMolecular weight:723.64Valrubicin
CAS:Controlled ProductApplications Chemotherapy drug used to treat cancer of the bladder.
References Steinberg, G., et al.: J. Urol., 163, 761 (2000); Christmann-Franck, S., et al.: J. Med. Chem., 47, 6840 (2004); McKiernan, J., et al.: J. Clin. Oncol., 24, 3075 (2006); Steinberg, G., et al.: Drug Evaluation, 2, 1009 (2001)Formula:C34H36F3NO13Color and Shape:NeatMolecular weight:723.64Valrubicin
CAS:Chemotherapy for bladder cancer; semi-synthetic analog of doxorubicinFormula:C34H36F3NO13Purity:Min. 95 Area-%Color and Shape:PowderMolecular weight:723.64 g/mol
